• LAST PRICE
    2.2600
  • TODAY'S CHANGE (%)
    Trending Down-0.0100 (-0.4405%)
  • Bid / Lots
    2.2500/ 1
  • Ask / Lots
    2.3100/ 3
  • Open / Previous Close
    2.3700 / 2.2700
  • Day Range
    Low 2.2600
    High 2.5000
  • 52 Week Range
    Low 1.8400
    High 9.0000
  • Volume
    7,014
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 2.31
TimeVolumeACHL
09:32 ET1002.37
09:45 ET2002.37
09:52 ET2002.4
10:06 ET6002.42
10:08 ET5002.49
10:12 ET1002.4
10:17 ET26002.5
10:19 ET5002.45
10:21 ET1002.4
10:30 ET1002.27
10:33 ET1002.27
10:35 ET1002.305
11:09 ET1002.3
11:27 ET1002.26
11:44 ET1002.31
11:54 ET5732.3044
12:21 ET1002.26
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesACHL
Achilles Therapeutics PLC
92.1M
-1.3x
---
United StatesMIRO
Miromatrix Medical Inc
91.5M
-3.3x
---
United StatesCADL
Candel Therapeutics Inc
90.7M
-3.7x
---
United StatesSNTI
Senti Biosciences Inc
94.1M
-27.1x
---
United StatesAXLA
Axcella Health Inc
90.0M
-1.0x
---
United StatesTRVI
Trevi Therapeutics Inc
89.8M
-1.7x
---
As of 2022-10-07

Company Information

Achilles Therapeutics plc is a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors. The Company has developed a bioinformatic platform called PELEUS, which is used to identify clonal neoantigens in patients. The Company's manufacturing process, VELOS, uses the patient’s T cells and blood-derived dendritic cells to create a clonal neoantigen targeting T cell therapy (cNeT). It's pipeline includes two single arm, open-label, proof-of-concept clinical trials in advanced non-small cell lung cancer (NSCLC) and metastatic or recurrent melanoma: CHIRON a Phase I clinical trial to evaluate the safety, tolerability and clinical activity of cNeT in up to 60 patients with advanced NSCLC, and THETIS a Phase I clinical trial to evaluate the safety, tolerability and clinical activity of cNeT in up to 60 patients with metastatic or recurrent melanoma.

Contact Information

Headquarters
245 Hammersmith Road, Gunnels Wood RoadLONDON, United Kingdom W6 8PW
Phone
208-154-4600
Fax
---

Executives

Non-Executive Independent Chairman of the Board
Edwin Moses
Chief Executive Officer, Executive Director
Iraj Ali
Chief Financial Officer
Robert Coutts
Chief Scientific Officer
Sergio Quezada
Chief Medical Officer
Karl Peggs

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$92.1M
Revenue (TTM)
$0.00
Shares Outstanding
40.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.70
Book Value
$7.13
P/E Ratio
-1.3x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.